JP2018500394A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2018500394A5 JP2018500394A5 JP2017550467A JP2017550467A JP2018500394A5 JP 2018500394 A5 JP2018500394 A5 JP 2018500394A5 JP 2017550467 A JP2017550467 A JP 2017550467A JP 2017550467 A JP2017550467 A JP 2017550467A JP 2018500394 A5 JP2018500394 A5 JP 2018500394A5
- Authority
- JP
- Japan
- Prior art keywords
- plga
- polymer
- sunitinib
- peg
- pharmaceutically acceptable
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000011859 microparticle Substances 0.000 claims 22
- 229920000642 polymer Polymers 0.000 claims 21
- 239000002147 L01XE04 - Sunitinib Substances 0.000 claims 14
- WINHZLLDWRZWRT-ATVHPVEESA-N Sunitinib Chemical compound CCN(CC)CCNC(=O)C1=C(C)NC(\C=C/2C3=CC(F)=CC=C3NC\2=O)=C1C WINHZLLDWRZWRT-ATVHPVEESA-N 0.000 claims 14
- 229920001606 poly(lactic acid-co-glycolic acid) Polymers 0.000 claims 14
- 229960001796 sunitinib Drugs 0.000 claims 14
- 239000000203 mixture Substances 0.000 claims 13
- 150000003839 salts Chemical class 0.000 claims 9
- 239000011780 sodium chloride Substances 0.000 claims 9
- 239000002202 Polyethylene glycol Substances 0.000 claims 5
- 229920001600 hydrophobic polymer Polymers 0.000 claims 5
- 229920001223 polyethylene glycol Polymers 0.000 claims 5
- 206010052639 Nerve injury Diseases 0.000 claims 3
- 229920001577 copolymer Polymers 0.000 claims 3
- 230000004410 intraocular pressure Effects 0.000 claims 3
- AEMRFAOFKBGASW-UHFFFAOYSA-N glycolic acid Chemical compound OCC(O)=O AEMRFAOFKBGASW-UHFFFAOYSA-N 0.000 claims 2
- 238000002347 injection Methods 0.000 claims 2
- 239000007924 injection Substances 0.000 claims 2
- 229940049920 malate Drugs 0.000 claims 2
- BJEPYKJPYRNKOW-UHFFFAOYSA-L malate(2-) Chemical compound [O-]C(=O)C(O)CC([O-])=O BJEPYKJPYRNKOW-UHFFFAOYSA-L 0.000 claims 2
- 229920000747 poly(lactic acid) polymer Polymers 0.000 claims 2
- 239000004626 polylactic acid Substances 0.000 claims 2
- 239000002904 solvent Substances 0.000 claims 2
- LBWFXVZLPYTWQI-IPOVEDGCSA-N N-[2-(diethylamino)ethyl]-5-[(Z)-(5-fluoro-2-oxo-1H-indol-3-ylidene)methyl]-2,4-dimethyl-1H-pyrrole-3-carboxamide;(2S)-2-hydroxybutanedioic acid Chemical group OC(=O)[C@@H](O)CC(O)=O.CCN(CC)CCNC(=O)C1=C(C)NC(\C=C/2C3=CC(F)=CC=C3NC\2=O)=C1C LBWFXVZLPYTWQI-IPOVEDGCSA-N 0.000 claims 1
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 claims 1
- 235000014655 lactic acid Nutrition 0.000 claims 1
- 239000004310 lactic acid Substances 0.000 claims 1
- 229960002812 sunitinib malate Drugs 0.000 claims 1
Claims (24)
- 両親媒性ポリマー及び/又は1つ以上の疎水性ポリマーのブレンド中に封入又は分散されたスニチニブ又はその薬学的に許容可能な塩を含む、眼圧上昇による眼の神経損傷の低減への使用のためのポリマーミクロ粒子。
- 前記疎水性ポリマーがポリ乳酸及び/又は乳酸とグリコール酸とのコポリマーを含む、請求項1に記載のポリマーミクロ粒子。
- 前記両親媒性ポリマーがペグ化疎水性ポリマーを含む、請求項1又は2に記載のポリマーミクロ粒子。
- 前記疎水性ポリマーがポリ(ラクチド−co−グリコリド)(PLGA)であり、前記両親媒性ポリマーがポリエチレングリコール(PEG)に結合したPLGAであり、
任意に約1ミクロン〜50ミクロンの平均径と約10重量%以上のスニチニブ又はその薬学的に許容可能な塩の重量装荷を有する、
請求項1〜3のいずれか一項に記載のポリマーミクロ粒子。 - 約1ミクロン〜50ミクロンの平均径を有する、請求項1〜3のいずれか一項に記載のポリマーミクロ粒子。
- 前記スニチニブ又はその薬学的に許容可能な塩が約5重量%超の量で存在する、請求項1〜3及び5のいずれか一項に記載のポリマーミクロ粒子。
- 前記PLGA及びPLGA−PEGが約99重量%のPLGAと1重量%のPLGA−PEGとの混合物で存在する、請求項4に記載のポリマーミクロ粒子。
- 前記PLGA−PEGコポリマーが分子量およそ45kDaのPLGA及び分子量およそ5kDaのPEGから形成される、請求項7に記載のポリマーミクロ粒子。
- 前記スニチニブ又はその薬学的に許容可能な塩が、両親媒性ポリマーと1種よりも多い疎水性ポリマーとのブレンド中に封入される、請求項1〜3及び5〜6のいずれか一項に記載のポリマーミクロ粒子。
- 少なくとも約10重量%以上のスニチニブ又はその薬学的に許容可能な塩を含み、約1ミクロン〜50ミクロンの平均径、好ましくは約1ミクロン〜30ミクロンの平均径を有するミクロ粒子を含む、眼圧上昇による眼の神経損傷の低減への使用のための組成物。
- 前記スニチニブ又はその薬学的に許容可能な塩が少なくとも約15重量%の量でミクロ粒子中に封入される、請求項10に記載の組成物。
- 前記ミクロ粒子がポリ(ラクチド−co−グリコリド)(PLGA)と、ポリ(ラクチド−co−グリコリド)−ポリエチレングリコール(PLGA−PEG)とのブレンド、好ましくは約99重量%のPLGAと1重量%のPLGA−PEGとの混合物を含む、請求項10〜11のいずれか一項に記載の組成物。
- 前記PLGA−PEGコポリマーが分子量およそ45kDaのPLGAと分子量およそ5kDaのPEGとを有する、請求項12に記載の組成物。
- 前記ミクロ粒子が少なくとも3ヶ月の持続期間に亘ってスニチニブを眼の硝子体腔に放出する、請求項10〜13のいずれか一項に記載の組成物。
- 前記スニチニブはアルカリ性溶媒系から得られ、任意に前記スニチニブはリンゴ酸塩の形態で存在する、請求項1〜9のいずれか一項に記載のポリマーミクロ粒子。
- 前記スニチニブはアルカリ性溶媒系から得られ、任意に前記スニチニブはリンゴ酸塩の形態で存在する、請求項10〜14のいずれか一項に記載の組成物。
- 1ミクロン〜50ミクロンの平均径を有し、PLGAとPLGA−PEGとのブレンド中に封入された5重量%超のスニチニブ又はその薬学的に許容可能な塩を含み、少なくとも2週間に亘って前記スニチニブを放出する、眼圧上昇による患者の眼の神経損傷の低減への使用のためのポリマーミクロ粒子。
- 前記患者がヒトである、請求項17に記載のポリマーミクロ粒子。
- 前記PLGAと前記PLGA−PEGが、約99重量%のPLGAと1重量%のPLGA−PEGとの混合物中に存在する、請求項17又は18に記載のポリマーミクロ粒子。
- さらにPLAを含む、請求項17〜19のいずれか一項に記載のポリマーミクロ粒子。
- 前記薬学的に許容可能な塩がリンゴ酸スニチニブである、請求項17〜20のいずれか一項に記載のポリマーミクロ粒子。
- 1ミクロン〜30ミクロンの平均径を有する、請求項17〜21のいずれか一項に記載のポリマーミクロ粒子。
- 硝子体内注射により投与される、請求項17〜22のいずれか一項に記載のポリマーミクロ粒子。
- 結膜下注射により投与される、請求項17〜22のいずれか一項に記載のポリマーミクロ粒子。
Applications Claiming Priority (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201462092118P | 2014-12-15 | 2014-12-15 | |
US62/092,118 | 2014-12-15 | ||
US201562139306P | 2015-03-27 | 2015-03-27 | |
US62/139,306 | 2015-03-27 | ||
PCT/US2015/065878 WO2016100380A1 (en) | 2014-12-15 | 2015-12-15 | Sunitinib formulations and methods for use thereof in treatment of glaucoma |
Publications (3)
Publication Number | Publication Date |
---|---|
JP2018500394A JP2018500394A (ja) | 2018-01-11 |
JP2018500394A5 true JP2018500394A5 (ja) | 2019-01-31 |
JP6847848B2 JP6847848B2 (ja) | 2021-03-24 |
Family
ID=55069169
Family Applications (3)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2017550469A Active JP6882186B2 (ja) | 2014-12-15 | 2015-12-15 | スニチニブ製剤及び眼の障害の治療におけるその使用に対する方法 |
JP2017550467A Active JP6847848B2 (ja) | 2014-12-15 | 2015-12-15 | スニチニブ製剤、及び緑内障の治療におけるその使用方法 |
JP2021078406A Pending JP2021119183A (ja) | 2014-12-15 | 2021-05-06 | スニチニブ製剤及び眼の障害の治療におけるその使用に対する方法 |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2017550469A Active JP6882186B2 (ja) | 2014-12-15 | 2015-12-15 | スニチニブ製剤及び眼の障害の治療におけるその使用に対する方法 |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2021078406A Pending JP2021119183A (ja) | 2014-12-15 | 2021-05-06 | スニチニブ製剤及び眼の障害の治療におけるその使用に対する方法 |
Country Status (19)
Country | Link |
---|---|
US (4) | US20170273901A1 (ja) |
EP (2) | EP3233058A1 (ja) |
JP (3) | JP6882186B2 (ja) |
KR (2) | KR20170094793A (ja) |
CN (3) | CN107278151A (ja) |
AU (2) | AU2015362621B2 (ja) |
BR (1) | BR112017012706A2 (ja) |
CA (1) | CA2972075C (ja) |
CO (1) | CO2017007003A2 (ja) |
EA (1) | EA201791337A1 (ja) |
HK (1) | HK1243942A1 (ja) |
IL (1) | IL252943A0 (ja) |
MX (1) | MX2017007873A (ja) |
NZ (1) | NZ733130A (ja) |
PH (1) | PH12017501097A1 (ja) |
RU (1) | RU2729731C2 (ja) |
SG (2) | SG10201903210WA (ja) |
WO (2) | WO2016100392A1 (ja) |
ZA (1) | ZA201703875B (ja) |
Families Citing this family (20)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2016100392A1 (en) * | 2014-12-15 | 2016-06-23 | The Johns Hopkins University | Sunitinib formulations and methods for use thereof in treatment of ocular disorders |
BR112018005589A2 (pt) | 2015-09-22 | 2018-10-09 | Graybug Vision Inc | “composto, composição farmaceuticamente aceitável, e, uso de um composto” |
CA3004886A1 (en) * | 2015-11-12 | 2017-05-18 | Graybug Vision, Inc. | Aggregating microparticles for medical therapy |
BR112019019452A2 (pt) | 2017-03-23 | 2020-04-14 | Graybug Vision Inc | composto, e, uso de um composto |
WO2018182527A1 (en) * | 2017-03-30 | 2018-10-04 | National University Of Singapore | Method for treating inflammatory complications in eye diseases |
WO2018209155A1 (en) | 2017-05-10 | 2018-11-15 | Graybug Vision, Inc. | Extended release microparticles and suspensions thereof for medical therapy |
WO2019016686A1 (en) * | 2017-07-17 | 2019-01-24 | Wolfcreek Biotech Pte Ltd | MICROPARTICLE FORMULATIONS FOR THE ADMINISTRATION OF ACTIVE AGENTS |
US20210113664A1 (en) * | 2018-06-25 | 2021-04-22 | Titan Pharmaceuticals, Inc. | Implants for release of lipophilic or amphiphilic pharmaceutical substances |
CN112566625A (zh) * | 2018-08-18 | 2021-03-26 | 夫特弗制药私人有限公司 | 口服剂量的化学治疗药物悬浮液 |
WO2020069353A1 (en) * | 2018-09-27 | 2020-04-02 | Graybug Vision, Inc. | Compounds and compositions for ocular delivery |
CN110946858A (zh) * | 2018-09-27 | 2020-04-03 | 中国科学院上海生命科学研究院 | 吲哚满酮衍生物在治疗肥胖及其相关疾病中的应用 |
KR102308227B1 (ko) * | 2018-10-31 | 2021-10-05 | 주식회사 삼양홀딩스 | 수니티닙을 함유하는 경구용 정제 조성물 |
KR102322429B1 (ko) * | 2018-10-31 | 2021-11-08 | 주식회사 삼양홀딩스 | 수니티닙을 함유하는 경구용 제제 및 그의 제조 방법 |
WO2020102758A1 (en) * | 2018-11-15 | 2020-05-22 | Graybug Vision, Inc. | Improved aggregated microparticles |
WO2020222541A1 (ko) * | 2019-04-30 | 2020-11-05 | 주식회사 엘지화학 | 캐스파제 저해제의 프로드럭 |
US11471412B1 (en) * | 2019-05-10 | 2022-10-18 | University Of South Florida | Nanoparticles and nanogel drug compositions for treatment of age-related macular degeneration |
CN110833425B (zh) * | 2019-11-27 | 2022-12-30 | 佛山科学技术学院 | 一种用于鸡胚采血的血管托持器 |
KR20240025990A (ko) * | 2022-08-19 | 2024-02-27 | 주식회사 스카이테라퓨틱스 | 무정형 수니티닙, 그 제조방법 및 이를 포함한 의약 조성물 |
KR20240028815A (ko) | 2022-08-25 | 2024-03-05 | 주식회사 스카이테라퓨틱스 | 약리 활성 물질의 신규 분자회합체 및 이를 포함하는 약학 조성물 |
WO2024095026A1 (en) | 2022-11-04 | 2024-05-10 | Semmelweis Egyetem | In vivo targeting of therapeutic molecules to the retina via the optical system of the eye |
Family Cites Families (111)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB929401A (en) | 1958-12-22 | 1963-06-19 | Upjohn Co | Encapsulated emulsions and processes for their preparation |
GB929405A (en) | 1958-12-22 | 1963-06-19 | Upjohn Co | Processes for the encapsulation of particles |
GB969808A (en) | 1962-06-08 | 1964-09-16 | Boots Pure Drug Co Ltd | Anthelmintic compositions and compounds |
IT1148784B (it) | 1980-04-09 | 1986-12-03 | Eurand Spa | Procedimento per la preparazione di microcapsule in un veicolo liquido |
US4794000A (en) | 1987-01-08 | 1988-12-27 | Synthetic Blood Corporation | Coacervate-based oral delivery system for medically useful compositions |
US4911920A (en) | 1986-07-30 | 1990-03-27 | Alcon Laboratories, Inc. | Sustained release, comfort formulation for glaucoma therapy |
US4997652A (en) | 1987-12-22 | 1991-03-05 | Visionex | Biodegradable ocular implants |
US4991920A (en) | 1988-12-27 | 1991-02-12 | Andrzej Peczalski | Optical converter |
US5019400A (en) | 1989-05-01 | 1991-05-28 | Enzytech, Inc. | Very low temperature casting of controlled release microspheres |
US5013556A (en) | 1989-10-20 | 1991-05-07 | Liposome Technology, Inc. | Liposomes with enhanced circulation time |
US5565215A (en) * | 1993-07-23 | 1996-10-15 | Massachusettes Institute Of Technology | Biodegradable injectable particles for imaging |
US5441722A (en) | 1994-02-18 | 1995-08-15 | Merck & Co., Inc. | Short synthesis of 5,6-dihydro-(S)-4-(ethylamino)-(S)-6-[C3 H3 ]-4[2,3-b]thiopyran-2-sulfonamide 7,7-dioxide and related non radioactive compounds |
GB9412273D0 (en) | 1994-06-18 | 1994-08-10 | Univ Nottingham | Administration means |
US6007845A (en) * | 1994-07-22 | 1999-12-28 | Massachusetts Institute Of Technology | Nanoparticles and microparticles of non-linear hydrophilic-hydrophobic multiblock copolymers |
CA2207961A1 (en) | 1995-01-05 | 1996-07-11 | Robert J. Levy | Surface-modified nanoparticles and method of making and using same |
US5624677A (en) | 1995-06-13 | 1997-04-29 | Pentech Pharmaceuticals, Inc. | Controlled release of drugs delivered by sublingual or buccal administration |
US6201072B1 (en) | 1997-10-03 | 2001-03-13 | Macromed, Inc. | Biodegradable low molecular weight triblock poly(lactide-co- glycolide) polyethylene glycol copolymers having reverse thermal gelation properties |
US6841617B2 (en) | 2000-09-28 | 2005-01-11 | Battelle Memorial Institute | Thermogelling biodegradable aqueous polymer solution |
US6703047B2 (en) | 2001-02-02 | 2004-03-09 | Incept Llc | Dehydrated hydrogel precursor-based, tissue adherent compositions and methods of use |
US6632457B1 (en) | 1998-08-14 | 2003-10-14 | Incept Llc | Composite hydrogel drug delivery systems |
US6818018B1 (en) | 1998-08-14 | 2004-11-16 | Incept Llc | In situ polymerizable hydrogels |
EP1137373A4 (en) | 1998-12-04 | 2004-05-19 | Chandrashekhar P Pathak | BIOCOMPATIBLE, CROSSLINKED POLYMERS |
US20040258763A1 (en) | 1999-02-03 | 2004-12-23 | Bell Steve J.D. | Methods of manufacture and use of calcium phosphate particles containing allergens |
US6217895B1 (en) | 1999-03-22 | 2001-04-17 | Control Delivery Systems | Method for treating and/or preventing retinal diseases with sustained release corticosteroids |
US6287588B1 (en) | 1999-04-29 | 2001-09-11 | Macromed, Inc. | Agent delivering system comprised of microparticle and biodegradable gel with an improved releasing profile and methods of use thereof |
US6589549B2 (en) | 2000-04-27 | 2003-07-08 | Macromed, Incorporated | Bioactive agent delivering system comprised of microparticles within a biodegradable to improve release profiles |
US6495164B1 (en) | 2000-05-25 | 2002-12-17 | Alkermes Controlled Therapeutics, Inc. I | Preparation of injectable suspensions having improved injectability |
US6706289B2 (en) | 2000-10-31 | 2004-03-16 | Pr Pharmaceuticals, Inc. | Methods and compositions for enhanced delivery of bioactive molecules |
GB0122318D0 (en) | 2001-09-14 | 2001-11-07 | Novartis Ag | Organic compounds |
US20040086532A1 (en) | 2002-11-05 | 2004-05-06 | Allergan, Inc., | Botulinum toxin formulations for oral administration |
US7060299B2 (en) | 2002-12-31 | 2006-06-13 | Battelle Memorial Institute | Biodegradable microparticles that stabilize and control the release of proteins |
WO2004084819A2 (en) * | 2003-03-19 | 2004-10-07 | University Of Kentucky Research Foundation | Poly(acryloyl-hydroxyethyl starch)-plga composite microspheres |
GB0307011D0 (en) | 2003-03-27 | 2003-04-30 | Regentec Ltd | Porous matrix |
PL1635875T3 (pl) | 2003-06-26 | 2009-03-31 | Psivida Inc | System dostarczania leków poprzez żelowanie w warunkach in-situ |
US20090148527A1 (en) | 2007-12-07 | 2009-06-11 | Robinson Michael R | Intraocular formulation |
WO2005072710A2 (en) | 2004-01-28 | 2005-08-11 | Johns Hopkins University | Drugs and gene carrier particles that rapidly move through mucous barriers |
ES2246694B1 (es) | 2004-04-29 | 2007-05-01 | Instituto Cientifico Y Tecnologico De Navarra, S.A. | Nanoparticulas pegiladas. |
US7799336B2 (en) | 2004-04-30 | 2010-09-21 | Allergan, Inc. | Hypotensive lipid-containing biodegradable intraocular implants and related methods |
US20050244472A1 (en) | 2004-04-30 | 2005-11-03 | Allergan, Inc. | Intraocular drug delivery systems containing excipients with reduced toxicity and related methods |
US9498457B2 (en) | 2004-04-30 | 2016-11-22 | Allergan, Inc. | Hypotensive prostamide-containing biodegradable intraocular implants and related implants |
US7771742B2 (en) | 2004-04-30 | 2010-08-10 | Allergan, Inc. | Sustained release intraocular implants containing tyrosine kinase inhibitors and related methods |
US8685435B2 (en) * | 2004-04-30 | 2014-04-01 | Allergan, Inc. | Extended release biodegradable ocular implants |
US7501179B2 (en) | 2005-12-21 | 2009-03-10 | Boston Scientific Scimed, Inc. | Block copolymer particles |
US20070149593A1 (en) | 2005-12-23 | 2007-06-28 | Alcon, Inc. | PHARMACEUTICAL FORMULATION FOR DELIVERY OF RECEPTOR TYROSINE KINASE INHIBITING (RTKi) COMPOUNDS TO THE EYE |
CA2636716C (en) | 2006-01-13 | 2014-12-23 | Surmodics, Inc. | Microparticle containing matrices for drug delivery |
US20080166411A1 (en) | 2006-04-10 | 2008-07-10 | Pfizer Inc | Injectable Depot Formulations And Methods For Providing Sustained Release Of Poorly Soluble Drugs Comprising Nanoparticles |
EP2061433B1 (en) | 2006-09-08 | 2011-02-16 | Johns Hopkins University | Compositions for enhancing transport through mucus |
GB0619869D0 (en) | 2006-10-07 | 2006-11-15 | Regentec Ltd | Porous particles |
MX2009004856A (es) | 2006-11-09 | 2009-06-05 | Alcon Res Ltd | Matriz polimerica insoluble en agua para suministro de farmaco. |
GB0701896D0 (en) | 2007-02-01 | 2007-03-14 | Regentec Ltd | Composition |
EP2121057A4 (en) | 2007-02-06 | 2012-10-10 | Incept Llc | POLYMERIZATION WITH PRECIPITATION OF PROTEINS FOR ELUTION IN A PHYSIOLOGICAL SOLUTION |
EP2178502A2 (en) | 2007-06-21 | 2010-04-28 | Yale University | Sustained delivery of drugs from biodegradable polymeric microparticles |
CN101081206A (zh) * | 2007-06-29 | 2007-12-05 | 济南康泉医药科技有限公司 | 一种含酪氨酸激酶抑制剂的抗癌药物组合物 |
US9125807B2 (en) | 2007-07-09 | 2015-09-08 | Incept Llc | Adhesive hydrogels for ophthalmic drug delivery |
AU2008315318B2 (en) | 2007-10-26 | 2014-02-06 | National Institute Of Immunology | Biodegradable polymer scaffold and process for preparation thereof |
US20090203709A1 (en) | 2008-02-07 | 2009-08-13 | Abbott Laboratories | Pharmaceutical Dosage Form For Oral Administration Of Tyrosine Kinase Inhibitor |
CA2717133C (en) | 2008-02-29 | 2016-04-26 | Nagoya Industrial Science Research Institute | Liposome for delivery to posterior segment of eye and pharmaceutical composition for disease in posterior segment of eye |
CN101336890A (zh) | 2008-05-30 | 2009-01-07 | 济南基福医药科技有限公司 | 一种抗癌缓释凝胶注射剂 |
WO2010017541A2 (en) * | 2008-08-08 | 2010-02-11 | The Johns Hopkins University | Compositions and methods for treatment of neurodegenerative disease |
WO2010030739A1 (en) | 2008-09-10 | 2010-03-18 | Abbott Laboratories | Polyethylene glycol lipid conjugates and uses thereof |
US9095506B2 (en) | 2008-11-17 | 2015-08-04 | Allergan, Inc. | Biodegradable alpha-2 agonist polymeric implants and therapeutic uses thereof |
RU2532345C2 (ru) | 2009-01-12 | 2014-11-10 | Хадасит Медикэл Рисёч Сервисес Энд Девелопмент Лимитэд | Мембрана для регенерации ткани |
JP5577354B2 (ja) | 2009-01-29 | 2014-08-20 | フォーサイト・ビジョン フォー・インコーポレーテッド | 治療装置 |
WO2010091187A2 (en) | 2009-02-04 | 2010-08-12 | The Brigham And Women's Hospital, Inc. | Polymeric nanoparticles with enhanced drug-loading and methods of use thereof |
AU2010213612B2 (en) | 2009-02-12 | 2015-04-30 | Incept, Llc | Drug delivery through hydrogel plugs |
MX2011008731A (es) | 2009-03-03 | 2011-09-29 | Alcon Res Ltd | Composicion farmaceutica para el suministro de compuestos inhibidores de la tirosina cinasa receptora (rtki) para los ojos. |
GB0903810D0 (en) | 2009-03-05 | 2009-04-22 | Regentec Ltd | Delivery system |
WO2010114770A1 (en) | 2009-03-30 | 2010-10-07 | Cerulean Pharma Inc. | Polymer-agent conjugates, particles, compositions, and related methods of use |
AU2010340067B2 (en) | 2009-12-15 | 2015-03-19 | Incept, Llc | Implants and biodegradable fiducial markers |
US8889193B2 (en) * | 2010-02-25 | 2014-11-18 | The Johns Hopkins University | Sustained delivery of therapeutic agents to an eye compartment |
US20130071349A1 (en) | 2010-03-02 | 2013-03-21 | Allergan, Inc. | Biodegradable polymers for lowering intraocular pressure |
WO2011119777A2 (en) * | 2010-03-23 | 2011-09-29 | The Johns Hopkins University | Compositions and methods for treatment of neurodegenerative disease |
WO2011119995A2 (en) * | 2010-03-26 | 2011-09-29 | Cerulean Pharma Inc. | Formulations and methods of use |
US10307372B2 (en) | 2010-09-10 | 2019-06-04 | The Johns Hopkins University | Rapid diffusion of large polymeric nanoparticles in the mammalian brain |
US8961501B2 (en) | 2010-09-17 | 2015-02-24 | Incept, Llc | Method for applying flowable hydrogels to a cornea |
US20120121718A1 (en) | 2010-11-05 | 2012-05-17 | The Johns Hopkins University | Compositions and methods relating to reduced mucoadhesion |
US9327037B2 (en) | 2011-02-08 | 2016-05-03 | The Johns Hopkins University | Mucus penetrating gene carriers |
WO2012112674A2 (en) * | 2011-02-15 | 2012-08-23 | The Johns Hopkins University | Compounds and methods of use thereof for treating neurodegenerative disorders |
US10226417B2 (en) | 2011-09-16 | 2019-03-12 | Peter Jarrett | Drug delivery systems and applications |
CN103127096B (zh) * | 2011-12-02 | 2015-11-25 | 杨子娇 | 吡咯基取代的吲哚类化合物在治疗青光眼病的应用 |
KR20190090048A (ko) | 2011-12-05 | 2019-07-31 | 인셉트, 엘엘씨 | 의료용 유기젤 방법 및 조성물 |
AU2012351994B2 (en) | 2011-12-14 | 2015-11-05 | The Johns Hopkins University | Nanoparticles with enhanced mucosal penetration or decreased inflammation |
US9415020B2 (en) | 2012-01-19 | 2016-08-16 | The Johns Hopkins University | Nanoparticle formulations with enhanced mucosal penetration |
AU2013232300B2 (en) | 2012-03-16 | 2015-12-17 | The Johns Hopkins University | Non-linear multiblock copolymer-drug conjugates for the delivery of active agents |
WO2013138343A1 (en) | 2012-03-16 | 2013-09-19 | The Johns Hopkins University | Controlled release formulations for the delivery of hif-1 inhibitors |
US20140107025A1 (en) | 2012-04-16 | 2014-04-17 | Jade Therapeutics, Llc | Ocular drug delivery system |
AU2013256130B2 (en) | 2012-05-03 | 2017-12-21 | Alcon Inc. | Pharmaceutical nanoparticles showing improved mucosal transport |
CN111700879A (zh) | 2012-05-03 | 2020-09-25 | 卡拉制药公司 | 显示提高的粘膜转移的药物纳米粒子 |
US9533068B2 (en) | 2012-05-04 | 2017-01-03 | The Johns Hopkins University | Drug loaded microfiber sutures for ophthalmic application |
AU2013256008B2 (en) | 2012-05-04 | 2016-02-25 | The Johns Hopkins University | Lipid-based drug carriers for rapid penetration through mucus linings |
US9539259B2 (en) * | 2012-05-23 | 2017-01-10 | The Johns Hopkins University | Compounds and methods of use thereof for treating neurodegenerative disorders |
JP2017512748A (ja) * | 2012-06-25 | 2017-05-25 | バイエル・ヘルスケア・エルエルシーBayer HealthCare LLC | スニチニブを含んでいる眼科用局所医薬組成物 |
WO2014043625A1 (en) * | 2012-09-17 | 2014-03-20 | Bind Therapeutics, Inc. | Therapeutic nanoparticles comprising a therapeutic agent and methods of making and using same |
CN103848985B (zh) * | 2012-11-30 | 2018-03-02 | 杨子剑 | 含有舒尼替尼类似物结构的新化合物以及制备方法和用途 |
RU2015146211A (ru) | 2013-04-01 | 2017-05-19 | Аллерган, Инк. | Микросферная система доставки лекарственного средства для замедленного внутриглазного высвобождения |
CN104208715B (zh) | 2013-05-31 | 2016-12-28 | 天津键凯科技有限公司 | 具有提高的药物生物活性的低分子量聚乙二醇药物结合物 |
WO2014203816A1 (ja) | 2013-06-18 | 2014-12-24 | 昭和電工株式会社 | コンデンサ陽極体およびその製造方法 |
US10646027B2 (en) | 2013-08-29 | 2020-05-12 | Sayeeda Mazed | Multifunctional personal care devices/apparatuses and compositions for hair or skin |
WO2015095772A2 (en) | 2013-12-20 | 2015-06-25 | Emory University | Formulations and methods for targeted ocular delivery of therapeutic agents |
KR101564401B1 (ko) | 2014-04-10 | 2015-11-02 | 한국화학연구원 | 브린졸아마이드의 제조방법 |
EP3193827A1 (en) | 2014-08-13 | 2017-07-26 | The Johns Hopkins University | Glucocorticoid-loaded nanoparticles for prevention of corneal allograft rejection and neovascularization |
US20160106587A1 (en) | 2014-10-16 | 2016-04-21 | Incept, Llc | Ocular gels or hydrogels and microinjectors |
WO2016065245A1 (en) | 2014-10-24 | 2016-04-28 | Incept, Llc | Extra luminal scaffold |
JP7092502B2 (ja) | 2014-12-10 | 2022-06-28 | インセプト・リミテッド・ライアビリティ・カンパニー | ハイドロゲル薬物送達インプラント |
WO2016100392A1 (en) * | 2014-12-15 | 2016-06-23 | The Johns Hopkins University | Sunitinib formulations and methods for use thereof in treatment of ocular disorders |
JP6479485B2 (ja) | 2015-01-15 | 2019-03-06 | 大内新興化学工業株式会社 | 眼疾患治療用ナノ粒子製剤 |
CN107206099A (zh) | 2015-01-20 | 2017-09-26 | 约翰霍普金斯大学 | 用于持续释放抗青光眼剂以控制眼内压的组合物 |
BR112017023762A2 (pt) | 2015-05-05 | 2018-07-31 | Psivida Us, Inc. | formulações de depósito injetáveis |
EP4279064A3 (en) | 2015-05-12 | 2024-02-28 | Incept, LLC | Drug delivery from hydrogels |
US10617563B2 (en) | 2015-07-22 | 2020-04-14 | Incept, Llc | Coated implants |
WO2017091749A1 (en) | 2015-11-25 | 2017-06-01 | Incept, Llc | Shape changing drug delivery devices and methods |
-
2015
- 2015-12-15 WO PCT/US2015/065894 patent/WO2016100392A1/en active Application Filing
- 2015-12-15 BR BR112017012706-7A patent/BR112017012706A2/pt not_active Application Discontinuation
- 2015-12-15 MX MX2017007873A patent/MX2017007873A/es unknown
- 2015-12-15 US US15/032,986 patent/US20170273901A1/en not_active Abandoned
- 2015-12-15 SG SG10201903210WA patent/SG10201903210WA/en unknown
- 2015-12-15 NZ NZ733130A patent/NZ733130A/en not_active IP Right Cessation
- 2015-12-15 SG SG11201704869VA patent/SG11201704869VA/en unknown
- 2015-12-15 RU RU2017123358A patent/RU2729731C2/ru active
- 2015-12-15 CA CA2972075A patent/CA2972075C/en active Active
- 2015-12-15 AU AU2015362621A patent/AU2015362621B2/en active Active
- 2015-12-15 EA EA201791337A patent/EA201791337A1/ru unknown
- 2015-12-15 JP JP2017550469A patent/JP6882186B2/ja active Active
- 2015-12-15 US US15/536,272 patent/US10525034B2/en active Active
- 2015-12-15 EP EP15831100.1A patent/EP3233058A1/en active Pending
- 2015-12-15 CN CN201580074275.2A patent/CN107278151A/zh active Pending
- 2015-12-15 CN CN201580074390.XA patent/CN107205940A/zh active Pending
- 2015-12-15 KR KR1020177019613A patent/KR20170094793A/ko unknown
- 2015-12-15 WO PCT/US2015/065878 patent/WO2016100380A1/en active Application Filing
- 2015-12-15 EP EP15820019.6A patent/EP3233056B1/en active Active
- 2015-12-15 CN CN202311531423.1A patent/CN117398350A/zh active Pending
- 2015-12-15 KR KR1020177019614A patent/KR20170094794A/ko unknown
- 2015-12-15 JP JP2017550467A patent/JP6847848B2/ja active Active
-
2017
- 2017-06-06 ZA ZA201703875A patent/ZA201703875B/en unknown
- 2017-06-13 PH PH12017501097A patent/PH12017501097A1/en unknown
- 2017-06-15 IL IL252943A patent/IL252943A0/en unknown
- 2017-07-12 CO CONC2017/0007003A patent/CO2017007003A2/es unknown
-
2018
- 2018-03-13 HK HK18103515.0A patent/HK1243942A1/zh unknown
-
2019
- 2019-03-25 AU AU2019202037A patent/AU2019202037B2/en active Active
- 2019-11-22 US US16/692,691 patent/US11013719B2/en active Active
-
2021
- 2021-04-12 US US17/228,423 patent/US20210251959A1/en not_active Abandoned
- 2021-05-06 JP JP2021078406A patent/JP2021119183A/ja active Pending
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP2018500394A5 (ja) | ||
JP2017537985A5 (ja) | ||
RU2017123358A (ru) | Составы на основе сунитиниба и способы их применения для лечения глазных заболеваний | |
US20230126007A1 (en) | Nanoparticles encapsulating soluble biologics, therapeutics, and imaging agents | |
Elzoghby et al. | Zein-based nanocarriers as potential natural alternatives for drug and gene delivery: focus on cancer therapy | |
Sun et al. | Sustained release of brimonidine from a new composite drug delivery system for treatment of glaucoma | |
Haggag et al. | Preparation and in vivo evaluation of insulin-loaded biodegradable nanoparticles prepared from diblock copolymers of PLGA and PEG | |
Lai et al. | Overview of the preparation of organic polymeric nanoparticles for drug delivery based on gelatine, chitosan, poly (d, l-lactide-co-glycolic acid) and polyalkylcyanoacrylate | |
Hathout et al. | Gelatin-based particulate systems in ocular drug delivery | |
ES2821526T3 (es) | Microesferas o micropartículas biodegradables o bioerosionables de liberación con el tiempo en suspensión en una formulación de fármaco inyectable de formación de depósito solidificante | |
WO2008157614A3 (en) | Sustained intraocular delivery of drugs from biodegradable polymeric microparticles | |
NZ595294A (en) | Intraocular sustained release drug delivery systems and methods for treating ocular conditions | |
JP2011528656A5 (ja) | ||
JP2018533596A5 (ja) | ||
Michalak et al. | Polymeric nanoparticles–a novel solution for delivery of antimicrobial agents | |
Patel et al. | Biodegradable polymers: Emerging excipients for the pharmaceutical and medical device industries | |
JP2018503736A5 (ja) | ||
JP2011503213A5 (ja) | ||
Park et al. | Enhanced ocular efficacy of topically-delivered dorzolamide with nanostructured mucoadhesive microparticles | |
RU2018105494A (ru) | Улучшенные системы доставки наночастиц | |
JP2015520241A5 (ja) | ||
Gavini et al. | Biodegradable microspheres as intravitreal delivery systems for prolonged drug release. What is their eminence in the nanoparticle era? | |
US20200023332A1 (en) | Method for controlling encapsulation efficiency and burst release of water soluble molecules from nanoparticles and microparticles produced by inverse flash nanoprecipitation | |
JPWO2019088214A1 (ja) | 徐放性医薬組成物 | |
Moayedian et al. | Combined effects of PEGylation and particle size on uptake of PLGA particles by macrophage cells |